For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
26
views
38
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      539
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Evaluación positiva de medicamentos: septiembre, octubre, noviembre y diciembre de 2021 Translated title: Positive assessment of drugs: from September, October, November and December of 2021

      brief-report
      Author(s): , , ,
      Publication date (Print and electronic):
      Journal: Sanidad Militar
      Publisher: Ministerio de Defensa
      Keywords: abrocitinib (Cibinqo®), amivantamab (Rybrevant®), anifrolumab (Saphnelo®), artesunato (Artesunato Amivas®), avacopan (Tavneos®), casirivimab/imdevimab (Ronapreve®), diroximel fumarato (Vumerity®), enfortumab vedotin (Padcev®), eptinezumab (Vyepti®), finerenona (Kerendia®), glucarpidasa (Voraxaze®), inebilizumab (Uplizna®), linzagolix colina (Yselty®), lonapegsomatropina (Lonapegsomatropin Ascendis Pharma®), pegcetacoplan (Aspaveli®), pralsetinib (Gavreto®), regdanvimab (Regkirona®), ripretinib (Qinlock®), risperidona (Okedi®), sacituzumab govitecan (Trodelvy®), semaglutida (Wegovy®), somatrogón (Ngenla®), sotorasib (Lumykras®), sotrovimab (Xevudy®), tecovirimat (Tecovirimat SIGA®), tepotinib (Tepmetko®), vacuna conjugada de polisacárido neumocócico adsorbido (Vaxneuvance®), vacuna conjugada de polisacáridos neumocócicos adsorbidos 20-valente (Apexxnar®), voxelotor (Oxbryta®), zanubrutinib (Brukinsa®), abrocitinib (Cibinqo®), amivantamab (Rybrevant®), anifrolumab (Saphnelo®), artesunato (Artesunato Amivas®), avacopan (Tavneos®), casirivimab/imdevimab (Ronapreve®), diroximel fumarato (Vumerity®), enfortumab vedotin (Padcev®), eptinezumab (Vyepti®), finerenona (Kerendia®), glucarpidasa (Voraxaze®), inebilizumab (Uplizna®), linzagolix colina (Yselty®), lonapegsomatropina (Lonapegsomatropin Ascendis Pharma®), pegcetacoplan (Aspaveli®), pralsetinib (Gavreto®), regdanvimab (Regkirona®), ripretinib (Qinlock®), risperidona (Okedi®), sacituzumab govitecan (Trodelvy®), semaglutida (Wegovy®), somatrogón (Ngenla®), sotorasib (Lumykras®), sotrovimab (Xevudy®), tecovirimat (Tecovirimat SIGA®), tepotinib (Tepmetko®), vacuna conjugada de polisacárido neumocócico adsorbido (Vaxneuvance®), vacuna conjugada de polisacáridos neumocócicos adsorbidos 20-valente (Apexxnar®), voxelotor (Oxbryta®), zanubrutinib (Brukinsa®)

      Read this article at

      SciELO
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          RESUMEN Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos de septiembre a diciembre de 2021, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento.

          Translated abstract

          SUMMARY The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public from September to December of 2021, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

          Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez … (2021)
          Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease.
          Article 0 comments Cited 516 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

            Aditya Bardia, Sara A Hurvitz, Sara M Tolaney … (2021)
            Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in the majority of breast cancers, coupled to SN-38 (topoisomerase I inhibitor) through a proprietary hydrolyzable linker.
            Article 0 comments Cited 480 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

              Paul K Paik, Enriqueta Felip, Rémi Veillon … (2020)
              A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population.
              Article 0 comments Cited 345 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (publisher-id): sm
                Title: Sanidad Militar
                Abbreviated Title: Sanid. Mil.
                Publisher: Ministerio de Defensa (Madrid, Madrid, Spain )
                ISSN (Print): 1887-8571
                Publication date (Print and electronic): March 2022
                Volume: 78
                Issue: 1
                Pages: 33-41
                Affiliations
                [1] Madrid orgnameHospital Central de la Defensa orgdiv1Servicio de Farmacia Hospitalaria
                [4] Madrid orgnameHospital Central de la Defensa orgdiv1Servicio de Farmacología Clínica
                [3] Madrid orgnameHospital Central de la Defensa orgdiv1Servicio de Farmacología Clínica
                [2] Madrid orgnameHospital Central de la Defensa orgdiv1Servicio de Farmacia Hospitalaria
                Article
                Publisher ID: S1887-85712022000100033 Publisher ID: S1887-8571(22)07800100033
                DOI: 10.4321/s1887-85712022000100007
                SO-VID: 43695b7a-7650-4d74-98d9-facefa5b9ddc
                License:

                http://creativecommons.org/licenses/by/4.0/

                History
                Date accepted : 10 March 2022
                Date received : 08 March 2022
                Page count
                Figures: 0, Tables: 0, Equations: 0, References: 39, Pages: 9
                Product

                SciELO Spain

                Categories
                Subject: Nota Técnica

                Keywords: zanubrutinib (Brukinsa®),voxelotor (Oxbryta®),vacuna conjugada de polisacáridos neumocócicos adsorbidos 20-valente (Apexxnar®),vacuna conjugada de polisacárido neumocócico adsorbido (Vaxneuvance®),tepotinib (Tepmetko®),tecovirimat (Tecovirimat SIGA®),sotrovimab (Xevudy®),sotorasib (Lumykras®),somatrogón (Ngenla®),semaglutida (Wegovy®),sacituzumab govitecan (Trodelvy®),risperidona (Okedi®),ripretinib (Qinlock®),regdanvimab (Regkirona®),pralsetinib (Gavreto®),pegcetacoplan (Aspaveli®),lonapegsomatropina (Lonapegsomatropin Ascendis Pharma®),linzagolix colina (Yselty®),inebilizumab (Uplizna®),glucarpidasa (Voraxaze®),finerenona (Kerendia®),eptinezumab (Vyepti®),enfortumab vedotin (Padcev®),diroximel fumarato (Vumerity®),casirivimab/imdevimab (Ronapreve®),avacopan (Tavneos®),artesunato (Artesunato Amivas®),anifrolumab (Saphnelo®),amivantamab (Rybrevant®),abrocitinib (Cibinqo®)
                Data availability:
                Keywords: zanubrutinib (Brukinsa®), voxelotor (Oxbryta®), vacuna conjugada de polisacáridos neumocócicos adsorbidos 20-valente (Apexxnar®), vacuna conjugada de polisacárido neumocócico adsorbido (Vaxneuvance®), tepotinib (Tepmetko®), tecovirimat (Tecovirimat SIGA®), sotrovimab (Xevudy®), sotorasib (Lumykras®), somatrogón (Ngenla®), semaglutida (Wegovy®), sacituzumab govitecan (Trodelvy®), risperidona (Okedi®), ripretinib (Qinlock®), regdanvimab (Regkirona®), pralsetinib (Gavreto®), pegcetacoplan (Aspaveli®), lonapegsomatropina (Lonapegsomatropin Ascendis Pharma®), linzagolix colina (Yselty®), inebilizumab (Uplizna®), glucarpidasa (Voraxaze®), finerenona (Kerendia®), eptinezumab (Vyepti®), enfortumab vedotin (Padcev®), diroximel fumarato (Vumerity®), casirivimab/imdevimab (Ronapreve®), avacopan (Tavneos®), artesunato (Artesunato Amivas®), anifrolumab (Saphnelo®), amivantamab (Rybrevant®), abrocitinib (Cibinqo®)

                Comments

                Comment on this article